- Home
- FDMT
as 05-30-2025 4:00pm EST
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 161.7M | IPO Year: | 2020 |
| Target Price: | $32.33 | AVG Volume (30 days): | 461.1K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $28.93 | Next Earning Date: | 05-08-2025 |
| Revenue: | $23,000 | Revenue Growth: | -99.89% |
| Revenue Growth (this year): | 13097.3% | Revenue Growth (next year): | -12.82% |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
4DMT to Participate in Upcoming Investor Conferences
Simply Wall St.
11 days ago
Spotlight On 3 Penny Stocks With Market Caps Under $500M
GlobeNewswire
16 days ago
4DMT Announces New Employment Inducement Grants
MT Newswires
20 days ago
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating
MT Newswires
23 days ago
RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk
Zacks
24 days ago
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
24 days ago
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
GlobeNewswire
a month ago
4DMT to Participate in Upcoming Investor Conferences
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.